Zobrazeno 1 - 10
of 15
pro vyhledávání: '"M. V. Papadopoulou"'
Autor:
Sarah Jane Lunt, Patricia M Price, Christopher Cawthorne, M V Papadopoulou, Alison Smigova, W Bloomer, Brian A. Telfer, Kaye J. Williams, Peter J Julyan, Ian J. Stratford, M. Babur, Majid Ali
Publikováno v:
British Journal of Cancer
British Journal of Cancer; Vol 103
British Journal of Cancer; Vol 103
Background: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of metastatic tumour growth. Methods: The NLCQ-1, RB6145 and tirapazamine were assessed again
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106b945c44a432cded82cdc125613758
https://doi.org/10.1038/sj.bjc.6605753
https://doi.org/10.1038/sj.bjc.6605753
Publikováno v:
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 15:219-231
Nitro(imidazole/triazole)-linked acridines (NLAs) have been previously developed in our laboratory as DNA-intercalating bioreductive drugs. Such compounds demonstrate toxicity through the formation of bulky monoadducts with cellular macromolecules up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38723273270eaa8178070bd4798c7a9e
https://doi.org/10.3727/096504005776382288
https://doi.org/10.3727/096504005776382288
Publikováno v:
Japanese Journal of Cancer Research : Gann
Two new bioreductive compounds, 9-[3-(2-nitro-1-imidazolyl)propylamino]acridine hydrochloride (NLA-1) and 9-[2-(2-nitro-1-imidazolyl)ethylamino]acridine hydrochloride (NLA-2), which behave as hypoxic cytotoxins and radiosensitizers, have been investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce843d365f8a34f99b4a058ade1b355
http://europepmc.org/articles/PMC5918954
http://europepmc.org/articles/PMC5918954
Publikováno v:
The British journal of radiology.
Hypoxia, or a lack of oxygen, occurs in 50-60% of solid human tumours. Clinical studies have shown that the presence and extent of hypoxia in a tumour cannot be predicted by size or histopathological stage but it is predictive of a poor outcome follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6d2d7a2228b54851d473e7ac9f36df
https://pubmed.ncbi.nlm.nih.gov/18819998
https://pubmed.ncbi.nlm.nih.gov/18819998
Publikováno v:
In vivo (Athens, Greece). 15(5)
19F-labeled bioreductive drugs bound to hypoxic cells in tumors could be detected by nuclear magnetic resonance, provided that they do not lose 19F during their metabolism. NLTQ-1, a 2-nitroimidazole-linked 7-trifluoromethylquinoline, has been synthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6f6ab9576d5f6779e84272a063dcb90
https://pubmed.ncbi.nlm.nih.gov/11695231
https://pubmed.ncbi.nlm.nih.gov/11695231
Publikováno v:
Oncology research. 11(8)
9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride (THNLA-1) is a 2-nitroimidazole-based, weakly DNA-intercalating bioreductive agent that significantly potentiates the toxic effects of commonly used antitumor drugs such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3addfaa98878f761b846c1b8ba486a5e
https://pubmed.ncbi.nlm.nih.gov/10803738
https://pubmed.ncbi.nlm.nih.gov/10803738
Publikováno v:
Oncology research. 10(3)
NLCPQ-1 is a novel, weak, DNA-affinic bioreductive compound with enhanced chemosensitizing ability for commonly used chemotherapeutic agents, both in vitro and in vivo. In the present report we investigated possible mechanisms involved in the potenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ce31ec07f67239b2c652553c37acf4d
https://pubmed.ncbi.nlm.nih.gov/9700727
https://pubmed.ncbi.nlm.nih.gov/9700727
Publikováno v:
Oncology research. 9(5)
9-(3-(2-Nitro-1-imidazolyl)propylamino]-cyclopentano[b]quinoline hydrochloride (NLCPQ-1) is one member of a limited series of 2-nitroimidazole-linked derivatized quinolines we have synthesized to be weak DNA binding compounds. On a concentration basi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e9464b6a2c3ffb7824ac389909a7b021
https://pubmed.ncbi.nlm.nih.gov/9306432
https://pubmed.ncbi.nlm.nih.gov/9306432
Publikováno v:
In vivo (Athens, Greece). 10(1)
THNLA-1 is a recently synthesized 2-nitroimidazole based, DNA-affinic bioreductive agent. It features a tetrahydroacridinic chromophore, which allows loose binding to DNA and therefore greater mobility along its backbone. THNLA-1 was proved to be a v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d2e19a42c4b215ccc9cbeb14bf66851b
https://pubmed.ncbi.nlm.nih.gov/8726811
https://pubmed.ncbi.nlm.nih.gov/8726811
Publikováno v:
Oncology research. 6(9)
Electron-affinic compounds with strong DNA intercalating properties have demonstrated less than the expected radiosensitization due to restriction of their mobility along the DNA backbone and their lower extravascular diffusion in tumors. A 2-nitroim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bed4c391b71a616662dce94ddbe3dae4
https://pubmed.ncbi.nlm.nih.gov/7703530
https://pubmed.ncbi.nlm.nih.gov/7703530